Eli Lilly Releases Phase III Data for Triple-Target Agonist

Stock News

Yesterday

Eli Lilly (LLY.US) released detailed results from the TRIUMPH-2 study on September 30, according to a report.

TRIUMPH-2 is a Phase III clinical trial designed to evaluate the efficacy and safety of retatrutide in adults who are obese or overweight and have type 2 diabetes.

Retatrutide is a polypeptide drug developed by Eli Lilly based on the GIP peptide sequence that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), the glucagon receptor (GCGR), and the gastric inhibitory polypeptide receptor (GIPR), with an average half-life of up to 6 days in the human body.

Retatrutide is currently the most advanced GLP-1R/GIPR/GCGR agonist in development. Eli Lilly plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.

Additional results from the obstructive sleep apnea trial within the TRIUMPH-2 study will be presented at future medical conferences and published in peer-reviewed journals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1124310828"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124310828\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124310828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 15:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124310828","market":"other","top_or_hot":-1,"title":"Eli Lilly Releases Phase III Data for Triple-Target Agonist","media":"Stock News","content":"<p>Eli Lilly (LLY.US) released detailed results from the TRIUMPH-2 study on September 30, according to a report.<br><br>TRIUMPH-2 is a Phase III clinical trial designed to evaluate the efficacy and safety of retatrutide in adults who are obese or overweight and have type 2 diabetes.<br><br>Retatrutide is a polypeptide drug developed by Eli Lilly based on the GIP peptide sequence that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), the glucagon receptor (GCGR), and the gastric inhibitory polypeptide receptor (GIPR), with an average half-life of up to 6 days in the human body.<br><br>Retatrutide is currently the most advanced GLP-1R/GIPR/GCGR agonist in development. Eli Lilly plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.<br><br>Additional results from the obstructive sleep apnea trial within the TRIUMPH-2 study will be presented at future medical conferences and published in peer-reviewed journals.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Releases Phase III Data for Triple-Target Agonist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Releases Phase III Data for Triple-Target Agonist\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-30 15:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly (LLY.US) released detailed results from the TRIUMPH-2 study on September 30, according to a report.<br><br>TRIUMPH-2 is a Phase III clinical trial designed to evaluate the efficacy and safety of retatrutide in adults who are obese or overweight and have type 2 diabetes.<br><br>Retatrutide is a polypeptide drug developed by Eli Lilly based on the GIP peptide sequence that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), the glucagon receptor (GCGR), and the gastric inhibitory polypeptide receptor (GIPR), with an average half-life of up to 6 days in the human body.<br><br>Retatrutide is currently the most advanced GLP-1R/GIPR/GCGR agonist in development. Eli Lilly plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.<br><br>Additional results from the obstructive sleep apnea trial within the TRIUMPH-2 study will be presented at future medical conferences and published in peer-reviewed journals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GCGR","symbol_name":"GENERAL CATALYST GLOBAL RESILIENCE MERGER CORP","start_time":0,"source_url":"","article_id":"1124310828","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124310828","pubTimestamp":1790752933,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Eli Lilly (LLY.US) released detailed results from the TRIUMPH-2 study on September 30, according to a report.TRIUMPH-2 is a Phase III clinical trial designed to evaluate the efficacy and safety of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GCGR":"GENERAL CATALYST GLOBAL RESILIENCE MERGER CORP","GIPR":"Generation Income Properties Inc.","BK4160":"多样化房地产投资信托v"},"translate_title":"礼来公司发布三靶点激动剂III期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GIPR":1,"GCGR":1},"content_text":"Eli Lilly (LLY.US) released detailed results from the TRIUMPH-2 study on September 30, according to a report.TRIUMPH-2 is a Phase III clinical trial designed to evaluate the efficacy and safety of retatrutide in adults who are obese or overweight and have type 2 diabetes.Retatrutide is a polypeptide drug developed by Eli Lilly based on the GIP peptide sequence that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), the glucagon receptor (GCGR), and the gastric inhibitory polypeptide receptor (GIPR), with an average half-life of up to 6 days in the human body.Retatrutide is currently the most advanced GLP-1R/GIPR/GCGR agonist in development. Eli Lilly plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.Additional results from the obstructive sleep apnea trial within the TRIUMPH-2 study will be presented at future medical conferences and published in peer-reviewed journals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}